EBioMedicine July 2017 PMID 28416161

Cellular Senescence: A Translational Perspective.

James L Kirkland, Tamara Tchkonia

Full text PDF Download social card

Mentions

Peak: 2 in Feb 2023

across 5 sources since Jan 2023

Extended reach

32,565

potential audience

Total likes

Video views

125

Mentions per month

Jan 2023 – Sep 2025

Where it's discussed

News11 articles
YouTube6 videos
Blogs4 articles
X / Twitter3 posts
Facebook2 posts

AI synopsis

What people are saying

Many discussions highlight the significance of senolytic drugs and the biological impact of cellular senescence, with words like 'important', 'exciting', and 'potential' indicating both interest and recognition of the publication's relevance. The tone ranges from cautious optimism to curiosity, emphasizing the scientific and medical implications of targeting senescent cells in aging.

AgreementModerate agreement

Most comments acknowledge the importance of the publication, with some expressing subtle enthusiasm for its potential impact.

InterestHigh interest

Discussions reflect a high level of curiosity, especially regarding the implications for aging and treatment strategies.

EngagementModerate engagement

Posts show moderate depth, with some referencing specific aspects like SASP, senolytic drugs, and cellular mechanisms.

ImpactModerate impact

The overall tone suggests that the publication could influence future research and therapeutic approaches, viewed as having notable potential.

Abstract in brief

Cellular senescence involves irreversible cell cycle arrest, resistance to cell death, and the release of pro-inflammatory factors called SASP, which contribute to aging and chronic diseases.
The buildup of senescent cells and their SASP can lead to inflammation, metabolic problems, stem cell dysfunction, and overall aging-related health decline.
Researchers are developing senolytic drugs that target pro-survival pathways in senescent cells (SCAPs), aiming to eliminate these cells and potentially treat or prevent age-related conditions, with some already moving into clinical testing.

Read the full abstract